Why Is FMC (FMC) Down 9.9% Since Last Earnings Report?
FMC (FMC) reported earnings 30 days ago. What's next for the stock?
FMC - FMC Corporation
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$15.00
DETAILS
HIGH:
$21.00
LOW:
$11.00
MEDIAN:
$15.00
CONSENSUS:
$15.00
UPSIDE:
15.65%
Stock News
FMC Corporation CEO Pierre Brondeau and CFO Andrew Sandifer to speak at the 2026 Jefferies Global Industrials Conference
PHILADELPHIA, Aug. 27, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC) today announced that Pierre Brondeau, FMC chairman, chief executive officer and president, and Andrew Sandifer, FMC executive vice president and chief financial officer, will speak at the 2026 Jefferies Global Industrials Conference on September 10, 2026 at 11:30 a.m. Eastern Time.
KBRA Assigns Ratings to FMC GMSR Issuer Trust, Series 2026-GT1 (FMC GMSR 2026-GT1)
NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns ratings of ‘BBB- (sf)' to the Series 2026-GT1, Class A Term Notes from FMC GMSR ISSUER TRUST, Freedom Mortgage Corporation's (FMC) master trust issuer of notes backed by a participation certificate evidencing a participation interest in mortgage servicing rights (MSR) on loans underlying Ginnie Mae guaranteed mortgage backed securities. KBRA's rating on the Series 2026-GT1 Term Notes is primarily driven by the credit rating of Freedom Mortgage Corporation.
Is the Options Market Predicting a Spike in FMC Stock?
Investors need to pay close attention to DAKT stock based on the movements in the options market lately.
Unlocking FMC (FMC) International Revenues: Trends, Surprises, and Prospects
Evaluate FMC's (FMC) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Dialysis firm FMC's shares slide despite earnings beat as US volumes disappoint again
Fresenius Medical Care shares fell in early trade on Tuesday, as investors looked past a second-quarter profit beat to focus on a fresh disappointment in U.S. patient volumes and the management's decision to merely confirm, not raise, the full-year guidance.
FMC (FMC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for FMC (FMC) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
FMC Q2 Earnings Call Highlights
FMC NYSE: FMC reported second-quarter revenue of $841 million excluding India, below the low end of its guidance range, as cautious customer purchasing, unfavorable weather, low insect pressure and pricing pressure weighed on demand. However, adjusted EBITDA of $153 million exceeded the high end of management's guidance by 2%, aided by cost discipline and favorable quarter-specific items.
FMC Corporation (FMC) Q2 2026 Earnings Call Transcript
FMC Corporation (FMC) Q2 2026 Earnings Call Transcript
Why FMC Corporation Rallied Today
FMC reported second quarter earnings that missed revenue expectations. Management also guided to a lower revenue and earnings target for the year.
FMC Q2 Earnings Beat Estimates on Favorable Costs, Revenues Miss
FMC's Q2 earnings beat estimates as cost gains offset weaker pricing and volumes. Revenues declined and 2026 sales guidance was cut.
FMC (FMC) Tops Q2 Earnings Estimates
FMC (FMC) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.69 per share a year ago.
FMC Corporation reports second quarter 2026 results with Adjusted EBITDA above high end of guidance range and solid cash generation
Updates full-year outlook to reflect more challenging macro environment; Company continues to focus on execution of operational priorities Second Quarter 2026 Highlights Revenue of $867 million, down 17 percent versus Q2 2025 Revenue excluding India1 of $841 million, down 20 percent versus Q2 2025 (which included India) Organic revenue2 for the period declined 22 percent Consolidated GAAP net loss of $187 million, a decline of $253 million versus Q2 2025 Adjusted EBITDA of $153 million, down 26 percent versus Q2 2025 Consolidated GAAP net loss of $1.49 per diluted share, down $2.02 versus Q2 2025 Adjusted earnings per diluted share of $0.26, down 62% versus Q2 2025 GAAP cash from operations of $363 million, an increase of $297 million versus Q2 2025 Full-Year Outlook 1 Revenue excluding India lowered to a range of $3.50 billion to $3.70 billion, a decline of 7 percent at the midpoint versus 2025 Excluding 2025 India contributions, the 2026 outlook represents a decline at the midpoint of 5 percent Adjusted EBITDA lowered to a range of $620 million to $680 million, a decline of 23 percent at the midpoint Adjusted earnings per diluted share lowered to a range of $1.19 to $1.49, a decline of 55 percent at the midpoint Free cash flow, which now includes the upfront licensing payment for rimisoxafen of $200 million, increased to a range of $75 million to $225 million PHILADELPHIA, July 29, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC) today reported second quarter 2026 revenue of $867 million, down 17 percent versus second quarter 2025. Second quarter 2026 revenue, excluding India, was $841 million, down 20 percent versus second quarter 2025, which included India.
FMC Corporation Declares Quarterly Dividend
PHILADELPHIA, July 23, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC) announced today that its board of directors declared a regular quarterly dividend of 8 cents per share, payable on October 15, 2026, to shareholders of record as of the close of business on September 30, 2026. About FMC FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment.
Analysts Estimate FMC (FMC) to Report a Decline in Earnings: What to Look Out for
FMC (FMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FMC Files First Global Regulatory Submission With EPA for Rimisoxafen
FMC's first global dossier for rimisoxafen seeks U.S. approval for a dual-action herbicide aimed at tough broadleaf weeds in major crops.
FMC Corporation Files First Global Regulatory Submission for Rimisoxafen with United States Environmental Protection Agency
The submission marks an important milestone in FMC's efforts to advance next-generation weed control technologies as resistance pressure intensifies in key row crop markets. PHILADELPHIA, July 8, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC), a leading global agricultural sciences company, today announced it has submitted the regulatory dossier for rimisoxafen to the United States (U.S.) Environmental Protection Agency (EPA), the first regulatory submission globally for this groundbreaking herbicide active ingredient.
FMC Lands $400M Minority Investment From Tessenderlo Group
FMC secures a $400 million investment from Tessenderlo Group to cut debt, strengthen liquidity and support crop protection technology growth.
FMC Corporation Reaches Agreement for $400 Million Minority Equity Investment from Tessenderlo Group
FMC Corporation Reaches Agreement for $400 Million Minority Equity Investment from Tessenderlo Group PR Newswire
FMC Corporation Reaches Agreement for $400 Million Minority Equity Investment from Tessenderlo Group
Tessenderlo Group's investment reflects its strategy of making cornerstone minority investments in high-quality companies Investment enables FMC to achieve approximately $1 billion debt paydown target FMC concludes strategic options review FMC maintains focus on delivering on its operational and strategic plan PHILADELPHIA and BRUSSELS, June 30, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC), a leading global agricultural sciences company, and Tessenderlo Group (XBRU: TESB), a Belgian-based industrial group, today announced that they have entered into a definitive agreement under which Tessenderlo Group will make a strategic minority equity investment in FMC Corporation of approximately $400 million USD at a price of $13.30 per share. Upon completion of the transaction, Tessenderlo Group will own approximately 20.0% of the outstanding shares of FMC common stock.
Price Targets
FMC price target lowered to $21 from $26 at Seaport Research
$21.00
(was $10.35)
Seaport Global
FMC price target lowered to $11 from $12 at RBC Capital
$11.00
(was $10.54)
Arun Viswanathan
·
RBC Capital
FMC price target lowered to $12 from $15.50 at Morgan Stanley
$12.00
(was $11.06)
Morgan Stanley
FMC price target lowered to $18 from $21 at Goldman Sachs
$18.00
(was $11.83)
Duffy Fischer
·
Goldman Sachs
FMC price target lowered to $11 from $13 at Barclays
$11.00
(was $11.30)
Barclays
FMC price target lowered to $16 from $20 at Mizuho
$16.00
(was $10.81)
Mizuho Securities
FMC price target lowered to $14 from $15 at BMO Capital
$14.00
(was $11.35)
BMO Capital
FMC price target raised to $17 from $14 at Wells Fargo
$17.00
(was $17.35)
Wells Fargo
FMC price target lowered to $20 from $21 at Mizuho
$20.00
(was $14.34)
Edlain Rodriguez
·
Mizuho Securities
FMC price target lowered to $15.50 from $17 at Morgan Stanley
$15.50
(was $14.43)
Morgan Stanley
FMC price target lowered to $14 from $16 at RBC Capital
$14.00
(was $14.29)
RBC Capital
FMC price target lowered to $14 from $15 at UBS
$14.00
(was $14.02)
UBS
FMC price target lowered to $14 from $16 at Wells Fargo
$14.00
(was $13.67)
Michael Sison
·
Wells Fargo
FMC price target lowered to $16 from $17 at RBC Capital
$16.00
(was $15.77)
Arun Viswanathan
·
RBC Capital
FMC price target lowered to $21 from $24 at Mizuho
$21.00
(was $15.48)
Mizuho Securities
FMC price target lowered to $15 from $17 at UBS
$15.00
(was $15.39)
UBS
FMC price target lowered to $24 from $30 at Mizuho
$24.00
(was $13.89)
Mizuho Securities
FMC downgraded to Underweight from Equal Weight at Barclays
$13.00
(was $13.10)
Benjamin Theurer
·
Barclays
FMC price target lowered to $17 from $38 at Morgan Stanley
$17.00
(was $14.33)
Morgan Stanley
FMC price target lowered to $17 from $33 at RBC Capital
$17.00
(was $15.53)
Arun Viswanathan
·
RBC Capital